Patents by Inventor Maoxu Ge

Maoxu Ge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis
    Patent number: 10933038
    Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: March 2, 2021
    Assignees: Hebei Medfaith Pharmaceutical Technology Co., Ltd., Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Hongwei Tian, Xingang Wang, Rongguang Shao, Yucheng Wang, Naren Li, Shi-Ying Cai, Hongwei He, Juxian Wang, Shuangshuang Zhao, Maoxu Ge, Jinfeng Ren
  • USE OF (BENZENESULFONAMIDO)BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS
    Publication number: 20190274979
    Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
    Type: Application
    Filed: November 24, 2016
    Publication date: September 12, 2019
    Applicants: Hebei Medfaith Pharmaceutical Technology Co., Ltd., Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences
    Inventors: Hongwei Tian, Xingang Wang, Rongguang Shao, Yucheng Wang, Naren Li, Shi-Ying Cai, Hongwei He, Juxian Wang, Shuangshuang Zhao, Maoxu Ge, Jinfeng Ren
  • USE OF (BENZENESULFONAMIDO) BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS
    Publication number: 20180333376
    Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
    Type: Application
    Filed: November 24, 2016
    Publication date: November 22, 2018
    Applicants: Hebei Medfaith Pharmaceutical Technology Co., Ltd., Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
    Inventors: Hongwei Tian, Xingang Wang, Rongguang Shao, Yucheng Wang, Naren Li, Shi-Ying Cai, Hongwei He, Juxian Wang, Shuangshuang Zhao, Maoxu Ge, Jinfeng Ren